Atezolizumab + Bevacizumab for Rare Cancers

Recruiting in Palo Alto (17 mi)

Kanwal P.S. Raghav | MD Anderson Cancer ...

Overseen byKanwal P. Raghav

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Research Team

Kanwal P. Raghav

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for patients with rare solid tumors like certain types of lung, anal, cervical, and other cancers. Participants must have measurable disease growth, adequate liver/kidney function, and be able to follow the study plan. They should not have severe allergies or autoimmune diseases, recent cancer treatments or investigational therapies within 28 days prior to the study.

Inclusion Criteria

Ability to comply with the study protocol, in the investigator's judgment

My cancer type matches the specific criteria listed.

My liver and kidney are working well.

See 6 more

Exclusion Criteria

I have not been excluded due to previous treatments or medications.

Pregnancy, breastfeeding, or intention to become pregnant during the study

I do not have autoimmune diseases, organ transplants, serious lung, infectious, or heart conditions.

See 5 more

Treatment Details

Interventions

Atezolizumab (Monoclonal Antibodies)
Bevacizumab (Monoclonal Antibodies)

Trial OverviewThe trial tests how well atezolizumab (an immunotherapy drug) combined with bevacizumab (a drug that inhibits blood vessel growth in tumors) works against various rare solid tumors. It's a phase II study focusing on the effectiveness of these monoclonal antibodies in stopping tumor growth.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Treatment (atezolizumab, bevacizumab)Experimental Treatment4 Interventions

Patients receive atezolizumab and bevacizumab IV over 60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.